All In Biotech

BLA 761328 · Astrazeneca Ab

Beyfortus

Nirsevimab-Alip · Injection · Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody

Novel

CDER novel approval, Jul 17, 2023: To prevent respiratory syncytial virus (RSV) lower respiratory tract disease

Last checked: Nov 20, 2026Latest source record: Apr 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Jul 17, 2023

Approved uses

3

Original approval plus efficacy supplements

Registered trials

14

5 Phase 3, 8 recruiting

FAERS reports

1,793

1,142 serious, 41 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 13, 2026.

BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season. Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. BEYFORTUS is a respiratory syncytial virus (RSV) F protein-directed fusion inhibitor indicated for the prevention of RSV lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season. ( 1 ) Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. ( 1 )

Mechanism: BEYFORTUS is a monoclonal antibody with anti-RSV activity [see Microbiology (12.4) ] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • BEYFORTUS · NIRSEVIMAB-ALIP 50MG · INJECTABLE, INJECTION · Prescription
  • BEYFORTUS · NIRSEVIMAB-ALIP 100MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nirsevimab" as an intervention, any sponsor and status, largest first.

All 14 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective324
  • respiratory syncytial virus bronchiolitis302
  • respiratory syncytial virus infection251
  • incorrect dose administered234
  • bronchiolitis157
  • pyrexia114
  • cough112
  • extra dose administered84
  • expired product administered50
  • respiratory syncytial virus test positive50
  • dyspnoea46
  • wheezing44

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2023143
2024450
2025772
2026428

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 32 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.